Home > Boards > Free Zone > Penny Trading - Technical > kairos notes

CANB DD

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
kairos Member Profile
Member Level 
Followed By 262
Posts 25,680
Boards Moderated 2
Alias Born 07/07/06
160x600 placeholder
kairos Member Level  Thursday, 01/24/19 09:33:03 PM
Re: kairos post# 899
Post # of 1033 
CANB DD

Excellent post by sleekscape summing up CANB

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146318931

CANB’S WINNING FORMULA

Yes, it looks like today’s news is going to open up an entirely different market for CANB

Just like last week’s news about Pure Leaf Oil

So now CANB is operating in 3 different markets — medical CBD, consumer CBD and medical device CBD, which is going to be an enormous market

When I picked CANB, I did so because of their business model of physicians selling medical grade CBD Oil products to patients — that being CANB’s core market separated them from every other publicly traded CBD Oil company

With Pure Leaf Oil as their new line of consumer CBD products available at retail stores, now like CVSI and CWBHF, they are set to sell their products in the biggest and most established market

And with the 3rd subsidiary announced today — DuraMed — they are targeting the medical device market, which is a brand new category with huge room for growth — with their connection to HudiLab and Mobius Therapy, which is the use of CBD-infused pads with TENS units, CANB has now added a 3rd revenue stream, but just as importantly, a 2nd differentiator

CANB = CVSI/CWBHF + Medical CBD + Medical device CBD

That is certainly going to be a winning formula for CANB in 2019

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146248339


Sleek


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist